Treating obesity: is it all in the gut?

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Obesity is a major global health concern, contributing significantly to preventable mortality.
• Current obesity treatments, including lifestyle changes, pharmacotherapy, and bariatric surgery, have limitations.
• Pharmacological interventions often yield modest patient benefits, necessitating the development of more effective therapies.

Purpose of the Study:

• To review novel therapeutic strategies for obesity focused on modulating anorectic gut hormones.
• To explore the potential of targeting specific gut hormones for substantial and sustainable weight management.
• To discuss the discovery of non-peptide agents acting on key hormonal pathways involved in appetite regulation.

Main Methods:

• Literature review of current research on obesity treatment strategies.
• Analysis of studies investigating the roles of glucagon-like peptide-1 (GLP-1), Ghrelin, and cholecystokinin (CCK) in appetite regulation.
• Examination of recent advancements in non-peptide small molecules targeting these hormonal pathways.

Main Results:

• Anorectic gut hormones represent a promising target for developing highly effective obesity treatments.
• Non-peptide small molecules targeting GLP-1, Ghrelin, and CCK pathways have been identified.
• These novel agents offer potential for significant weight loss, potentially rivaling bariatric surgery outcomes.

Conclusions:

• Modulating anorectic gut hormones offers a promising avenue for developing next-generation obesity therapeutics.
• Targeting these pathways may provide substantial efficacy for weight management, potentially surpassing current pharmacological options.
• Future research should focus on the clinical translation of these non-peptide agents to address the global obesity epidemic.